Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 201–300 of 1,031
Silva, S. R. D., Arno, G., Robson, A. G., Fakin, A., Pontikos, N., Mohamed, M. D., Bird, A. C., Moore, A. T., Michaelides, M., Webster, A. R., et al. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100898 · Cited by 172
Vandenberghe, L. H., Xiao, R., Lock, M., Lin, J., Korn, M., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.107 · Cited by 151
“These studies demonstrated the potential of this vector platform and provided the first convincing clinical success for in vivo gene therapy, in patients with Leber’s congenital amaurosis (Bainbridge et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008).”
Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells
VandenDriessche, T., Ivics, Z., Izsvák, Z., & Chuah, M. K. L. (2009) · Blood · doi:10.1182/blood-2009-04-210427 · Cited by 151
Burnham, B., Nass, S., Kong, E., Mattingly, M., Woodcock, D., Song, A., Wadsworth, S., Cheng, S. H., Scaria, A., & O'Riordan, C. R. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.048 · Cited by 150
The Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
“Nevertheless, there can be complications as with any surgery, and in the case of subretinal delivery, these can include those that have been reported in the various LCA2 clinical trials, including macular hole (Maguire et al. 2008; Simonelli et al. 2010), unresolved retinal detachment requiring surgical repair, choroi…”
BackgroundInfluentialSelf-citationBramall, A. N., Wright, A. F., Jacobson, S. G., & McInnes, R. R. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153227 · Cited by 149
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 147
Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes
Nass, S. A., Mattingly, M. A., Woodcock, D. A., Burnham, B. L., Ardinger, J. A., Osmond, S. E., Frederick, A. M., Scaria, A., Cheng, S. H., & O’Riordan, C. R. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.004 · Cited by 146
Translational nanomedicine: status assessment and opportunities
Murday, J. S., Siegel, R. W., Stein, J. A., & Wright, J. F. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.06.001 · Cited by 176
Self-citationAAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye
Reichel, F. F., Dauletbekov, D. L., Klein, R., Peters, T., Ochakovski, G. A., Seitz, I. P., Wilhelm, B., Ueffing, M., Biel, M., Wissinger, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.018 · Cited by 145
Park, T. K., Wu, Z., Kjellstrom, S., Zeng, Y., Bush, R. A., Sieving, P. A., & Colosi, P. (2009) · Gene Therapy · doi:10.1038/gt.2009.61 · Cited by 145
Coppieters, F., Casteels, I., Meire, F., De Jaegere, S., Hooghe, S., van Regemorter, N., Van Esch, H., Matulevičienė, A., Nunes, L., Meersschaut, V., et al. (2010) · Human Mutation · doi:10.1002/humu.21336 · Cited by 144
“Recent Phase I clinical trials for RPE65 gene replacement therapy provide hopeful prospects for the treatment of inherited retinal dystrophies (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009).”
BackgroundHellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142
Genome Editing Abrogates Angiogenesis in Vivo
Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., Xiao, R., Vandenberghe, L., Zhang, F., D’Amore, P. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00140-3 · Cited by 142
Hippert, C., Graca, A. B., Barber, A. C., West, E. L., Smith, A. J., Ali, R. R., & Pearson, R. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120415 · Cited by 155
“In the past few years, great progress has been made in the development of novel ocular therapies such as electronic implants [68] and in the field of both cell [6,69] and gene therapy [5,70,71].”
BackgroundAAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression
Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., Lorenc, V. E., Chen, D., Chadha, R., Zhang, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129085 · Cited by 141
Millington-Ward, S., Chadderton, N., O'Reilly, M., Palfi, A., Goldmann, T., Kilty, C., Humphries, M., Wolfrum, U., Bennett, J., Humphries, P., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.293 · Cited by 141
“Recent clinical trials employing AAV-mediated subretinal delivery of an RPE65 replacement gene for Leber Congenital Amaurosis (LCA) have suggested that AAV is well tolerated in the human eye and have promoted the use of AAV for retinal gene delivery (2, 3, 4, 5, 6, 7).”
Self-citationSahel, J.-A., & Roska, B. (2013) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170304 · Cited by 140
“In humans, phase I clinical trials simultaneously conducted by three different groups demonstrated that AAV-mediated RPE65 gene therapy was safe and led to a slight improvement in vision, mostly under dark-adapted conditions (Bainbridge et al. 2008, Hauswirth et al. 2008, Maguire et al. 2008).”
BackgroundRPGR: Its role in photoreceptor physiology, human disease, and future therapies
Megaw, R. D., Soares, D. C., & Wright, A. F. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.06.007 · Cited by 139
Amado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140
Self-citationLong-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139
“Because of the small number of samples in our study, we adopted previously used protocols (Maguire et al., 2008; Bainbridge et al., 2008) regarding BCVA analysis for small sample sizes.”
BackgroundMethodExome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis
Chiang, P.-W., Wang, J., Chen, Y., Fu, Q., Zhong, J., Chen, Y., Yi, X., Wu, R., Gan, H., Shi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.2370 · Cited by 147
Mingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
“With few exceptions, like direct intramuscular injection 14,17,27 , subretinal delivery 16,28,29 , and intracranial delivery 15 , vector administration to any body compartment in which immunoglobulins are present faces the hurdle of anti-AAV antibodies.”
Self-citationThe human visual cortex responds to gene therapy–mediated recovery of retinal function
Ashtari, M., Cyckowski, L. L., Monroe, J. F., Marshall, K. A., Chung, D. C., Auricchio, A., Simonelli, F., Leroy, B. P., Maguire, A. M., Shindler, K. S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57377 · Cited by 138
“There were no significant changes in contrast sensitivity in any of the eyes/subjects, as assessed with the Pelli-Robson contrast sensitivity chart, prior to and after gene transfer (16, 17).”
BackgroundMethodInfluentialSelf-citationSafety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137
Collin, R. W., den Hollander, A. I., van der Velde-Visser, S. D., Bennicelli, J., Bennett, J., & Cremers, F. P. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.3 · Cited by 137
Self-citationRescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
Puzzo, F., Colella, P., Biferi, M. G., Bali, D., Paulk, N. K., Vidal, P., Collaud, F., Simon-Sola, M., Charles, S., Hardet, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6375 · Cited by 135
“Among gene delivery vectors, clinical experience with adeno-associated virus (AAV) vectors for diseases like hemophilia (11) and congenital blindness (12) has established this system as safe and effective for in vivo gene transfer (13).”
BackgroundSelf-citationCampochiaro, P. A., Avery, R., Brown, D. M., Heier, J. S., Ho, A. C., Huddleston, S. M., Jaffe, G. J., Khanani, A. M., Pakola, S., Pieramici, D. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00310-6 · Cited by 135
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
“…on efficiency, as seen in clinical trials for Leber’s congenital amaurosis (LCA2) patients (Bainbridge et al, 2008; Hauswirth et al, 2008; Maguire et al, 2008) where photoreceptor degeneration continued even after subretinal gene therapy with an rAAV2-RPE65 vector (Cideciyan et al,…”
BackgroundPernet, V., Joly, S., Dalkara, D., Jordi, N., Schwarz, O., Christ, F., Schaffer, D. V., Flannery, J. G., & Schwab, M. E. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.011 · Cited by 133
“Received 31 August 2012 Revised 26 October 2012 Accepted 14 November 2012 Available online 27 November 2012”
BackgroundSlijkerman, R. W., Vaché, C., Dona, M., García-García, G., Claustres, M., Hetterschijt, L., Peters, T. A., Hartel, B. P., Pennings, R. J., Millan, J. M., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.89 · Cited by 134
O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.162 · Cited by 146
Tseng, Y.-S., & Agbandje-McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 134
Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Lundberg, C., Bjorklund, T., Carlsson, T., Jakobsson, J., Hantraye, P., Deglon, N., & Kirik, D. (2008) · Current Gene Therapy · doi:10.2174/156652308786847996 · Cited by 134
“In the light of the success of recent clinical trials in the eye using AAV based vectors [25, 26] it is fair to presume that also lentiviral vectors have a future in gene therapy for ocular disorders.”
BackgroundBonnet, C., & El-Amraoui, A. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834ef8b2 · Cited by 132
Zhang, Y., Ivanova, E., Bi, A., & Pan, Z.-H. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0184-09.2009 · Cited by 132
“Recently, rAAV vectors have been used in human clinical trials to treat other retinal degenerative diseases (Maguire et al., 2008).”
BackgroundMarkusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material
Lock, M., McGorray, S., Auricchio, A., Ayuso, E., Beecham, E. J., Blouin-Tavel, V., Bosch, F., Bose, M., Byrne, B. J., Caton, T., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.223 · Cited by 131
“…due to the demonstration of long-term transgene expression in animal models with little associated toxicity and good overall safety profiles in humans (Snyder and Flotte, 2002; Moss et al. , 2004; Warrington and Herzog, 2006; Maguire et al. , 2008; Mueller and Flotte, 2008; Brantly et al. , 2009).”
Self-citationNovel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Self-citationGene therapy: progress and predictions
Collins, M. K., & Thrasher, A. J. (2015) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2014.3003 · Cited by 178
Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients
Liu, Y., Chen, S. J., Li, S., Qu, L. H., Meng, X. H., Wang, Y. H., Xu, H., Liang, Z. Q., & Yin, Z. Q. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0661-8 · Cited by 145
Transient transfection methods for clinical adeno-associated viral vector production
Wright, J. F. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.064 · Cited by 131
Self-citationThe Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Targets of Neuroprotection in Glaucoma
He, S., Stankowska, D. L., Ellis, D. Z., Krishnamoorthy, R. R., & Yorio, T. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0041 · Cited by 140
“The use of AAV to target gene expression has also emerged as a safe and promising approach for the treatment of ocular disorders after the successful phase 1 clinical trial for Leber’s Congenital Amaurosis using AAV-mediated gene delivery of the RPE65 gene.(191,192) In a rat model of glaucoma, AAV-mediated BDNF expres…”
MethodNishiguchi, K. M., Tearle, R. G., Liu, Y. P., Oh, E. C., Miyake, N., Benaglio, P., Harper, S., Koskiniemi-Kuendig, H., Venturini, G., Sharon, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308243110 · Cited by 129
Let There Be Light: Gene and Cell Therapy for Blindness
Dalkara, D., Goureau, O., Marazova, K., & Sahel, J.-A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.147 · Cited by 129
Review and update on the molecular basis of Leber congenital amaurosis
Chacon-Camacho, O. F. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i2.112 · Cited by 128
Topographical characterization of cone photoreceptors and the area centralis of the canine retina.
Mowat, F. M., Petersen‐Jones, S. M., WILLIAMSON, H. S., Williams, D. L., Luthert, P. J., Ali, R. R., & Bainbridge, J. W. (2008) · PubMed Central · Cited by 126
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Self-citationGene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
“Beginning in 2007, multiple phase I/IIa trials of subretinal delivery of RPE65 cDNA using AAV2 resulted in no serious adverse events and showed improvements in visual acuity, pupillary reflexes, and mobility in some treated patients (25, 60, 61).”
BackgroundCEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype
Burnight, E. R., Wiley, L. A., Drack, A. V., Braun, T. A., Anfinson, K. R., Kaalberg, E. E., Halder, J. A., Affatigato, L. M., Mullins, R. F., Stone, E. M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.39 · Cited by 127
Self-citationRod-Derived Cone Viability Factor for Treating Blinding Diseases: From Clinic to Redox Signaling
Léveillard, T., & Sahel, J.-A. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000866 · Cited by 127
Giannelli, S. G., Luoni, M., Castoldi, V., Massimino, L., Cabassi, T., Angeloni, D., Demontis, G. C., Leocani, L., Andreazzoli, M., & Broccoli, V. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx438 · Cited by 127
“Nonetheless, very recent studies have shown that this administration route might lead to some moderate systemic inflammation that might worsen the overall pathological state (21,22).”
BackgroundEpilepsy Gene Therapy Using an Engineered Potassium Channel
Snowball, A., Chabrol, E., Wykes, R. C., Shekh-Ahmad, T., Cornford, J. H., Lieb, A., Hughes, M. P., Massaro, G., Rahim, A. A., Hashemi, K. S., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1143-18.2019 · Cited by 127
“, 2017), Leber’s congenital amaurosis (Maguire et al., 2008), and choroideremia (MacLaren et al.”
BackgroundCellular strategies for retinal repair by photoreceptor replacement
Jayakody, S. A., Gonzalez-Cordero, A., Ali, R. R., & Pearson, R. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.01.003 · Cited by 140
“…in (Jones et al., 2003; Jones and Marc, 2005; Vugler, 2010)], but nonetheless, the extensive evidence from gene therapy (Bainbridge et al., 2008; Maguire et al., 2008) and the use of retinal implant devices (Caspi et al., 2009; Humayun et al., 2009) demonstrates that it is possible to restore…”
Noninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
“As an example, the results from the choroideremia (CHM) gene therapy trial (NCT01461213) showed a high degree of safety associated with subretinal injections targeting the fovea [36,37], a concern that had been raised in the previous LCA2 trials [38,39].”
ResultSelf-citationChadderton, N., Millington-Ward, S., Palfi, A., O'Reilly, M., Tuohy, G., Humphries, M. M., Li, T., Humphries, P., Kenna, P. F., & Farrar, G. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.301 · Cited by 124
Sun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., Khani, S. C., Tan, M.-H., Smith, A. J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.104 · Cited by 123
RetractedDefining the Residual Vision in Leber Congenital Amaurosis Caused by RPE65 Mutations
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Windsor, E. A. M., Schwartz, S. B., Heon, E., & Stone, E. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2696 · Cited by 121
“There is not yet any proof of efficacy in terms of foveal visual acuity and the occurrence of a complicating macular hole certainly indicates that foveomacular injections carry some increased complication risks.(12) We suggest that perifoveal or mid-peripheral subretinal injection sites be considered as alternate targ…”
Self-citationEngineering Biomaterial Systems to Enhance Viral Vector Gene Delivery
Jang, J.-H., Schaffer, D. V., & Shea, L. D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.111 · Cited by 123
Adeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
New insights into retinoid metabolism and cycling within the retina
Tang, P. H., Kono, M., Koutalos, Y., Ablonczy, Z., & Crouch, R. K. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.002 · Cited by 122
“Gene therapy studies on mouse (Pang et al., 2006) and canine (Acland et al., 2001, 2005) models, as well as LCA2 patients (Bainbridge et al., 2008; Maguire et al., 2008, 2009), have shown that inserting a functional gene for RPE65 into RPE cells holds great promise for restoring visual function.”
Lignin Nanotubes As Vehicles for Gene Delivery into Human Cells
Ten, E., Ling, C., Wang, Y., Srivastava, A., Dempere, L. A., & Vermerris, W. (2013) · Biomacromolecules · doi:10.1021/bm401555p · Cited by 132
Unravelling the genetics of inherited retinal dystrophies: Past, present and future
Broadgate, S., Yu, J., Downes, S. M., & Halford, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.003 · Cited by 137
Adeno-associated virus: fit to serve
Zinn, E., & Vandenberghe, L. H. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.07.008 · Cited by 122
“When loaded with a therapeutic transgene, clinical safety and efficacy of AAV has been shown for inherited forms of blindness[3,4] and hemophilia B[5].”
BackgroundLakowski, J., Han, Y.-T., Pearson, R. A., Gonzalez-Cordero, A., West, E. L., Gualdoni, S., Barber, A. C., Hubank, M. J. F., Ali, R. R., & Sowden, J. C. (2011) · Stem Cells · doi:10.1002/stem.694 · Cited by 128
Inner Ear Gene Therapies Take Off: Current Promises and Future Challenges
Delmaghani, S., & El-Amraoui, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072309 · Cited by 136
Chung, D. C., & Traboulsi, E. I. (2009) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.004 · Cited by 138
Retinitis pigmentosa and allied conditions today: a paradigm of translational research
Ayuso, C., & Millán, J. M. (2010) · Genome Medicine · doi:10.1186/gm155 · Cited by 147
“Phase I clinical trials of gene therapy targeting the gene RPE65 [4951] are being conducted in three different medical centers: Moorfields Eye Hospital, UK [49], the Children’s Hospital of Philadelphia, USA, [51], and the Universities of Pennsylvania and Florida, USA.”
BackgroundDrug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
“Similarly, subretinal vector delivery has been performed in a number of clinical studies (28, 33).”
BackgroundNeurotrophic factor delivery as a protective treatment for glaucoma
Johnson, T. V., Bull, N. D., & Martin, K. R. G. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.05.016 · Cited by 128
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
von Lintig, J., Kiser, P. D., Golczak, M., & Palczewski, K. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.01.005 · Cited by 119
Tan, M. H., Smith, A. J., Pawlyk, B., Xu, X., Liu, X., Bainbridge, J. B., Basche, M., McIntosh, J., Tran, H. V., Nathwani, A., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp133 · Cited by 119
“Although the patients involved in these trials were predominantly adults and have established retinal degeneration, the preliminary results suggest some improvement in visual function is possible (12,13), paving the way for additional clinical trials of gene therapy for a variety of inherited retinal degenerations.”
BackgroundEngineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 118
“Adenovirus (506) Retrovirus (420) Plasmid DNA (397) Vaccinia virus (165) Adeno-associated virus (137) Lipofection (115) Lentivirus (114) Poxvirus (101) Herpes simplex virus (73) Other vector (174) Unknown vector (76)”
BackgroundInfluentialCideciyan, A. V., Swider, M., Aleman, T. S., Feuer, W. J., Schwartz, S. B., Russell, R. C., Steinberg, J. D., Stone, E. M., & Jacobson, S. G. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8415 · Cited by 118
Self-citationMessenger RNA therapy for rare genetic metabolic diseases
Berraondo, P., Martini, P. G. V., Avila, M. A., & Fontanellas, A. (2019) · Gut · doi:10.1136/gutjnl-2019-318269 · Cited by 118
Boye, S. E., Alexander, J. J., Boye, S. L., Witherspoon, C. D., Sandefer, K. J., Conlon, T. J., Erger, K., Sun, J., Ryals, R., Chiodo, V. A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.125 · Cited by 117
“However, these levels were not sustained nor did they compromise the efficacy of a second subretinal injection in the contralateral eye (Bennett et al. , 2012; Maguire et al. , 2008; Simonelli et al. , 2010).”
Self-citationArruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117
Self-citationSlijkerman, R. W. N., Song, F., Astuti, G., Huynen, M. A., van Wijk, E., Stieger, K., & Collin, R. W. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.004 · Cited by 137
Binley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Self-citationMeliani, A., Leborgne, C., Triffault, S., Jeanson-Leh, L., Veron, P., & Mingozzi, F. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.037 · Cited by 114
Self-citationIn vivo genome editing via the HITI method as a tool for gene therapy
Suzuki, K., & Belmonte, J. C. I. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0352-4 · Cited by 133
“For example, the initial results of a clinical trial for Leber’s congenital amaurosis, a blindness disease, indicated that non-integrating adeno-associated viral (AAV) vector delivery of transgenes was safe and showed therapeutic efficacy in repairing human visual function [2, 3].”
Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options
Hirji, N., Aboshiha, J., Georgiou, M., Bainbridge, J., & Michaelides, M. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2017.1418389 · Cited by 114
AAV-Mediated Cone Rescue in a Naturally Occurring Mouse Model of CNGA3-Achromatopsia
Pang, J.-J., Deng, W.-T., Dai, X., Lei, B., Everhart, D., Umino, Y., Li, J., Zhang, K., Mao, S., Boye, S. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035250 · Cited by 114
“In addition, the RPE65-LCA clinical trials have demonstrated the ability of the CBA promoter to support therapeutic transgene expression in the retina and restoration of visual function [29–33].”
BackgroundAdeno-Associated Virus Structural Biology as a Tool in Vector Development
Drouin, L. M., & Agbandje-McKenna, M. (2013) · Future Virology · doi:10.2217/fvl.13.112 · Cited by 114
Banin, E., Gootwine, E., Obolensky, A., Ezra-Elia, R., Ejzenberg, A., Zelinger, L., Honig, H., Rosov, A., Yamin, E., Sharon, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.114 · Cited by 113
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“Multiple trials have documented the ocular injections of AAV vector, to be safe and efficacious with evidence of improved visual function in the patients with LCA [63,64].”
BackgroundRetinal gene therapy with a large MYO7A cDNA using adeno-associated virus
Lopes, V. S., Boye, S. E., Louie, C. M., Boye, S., Dyka, F., Chiodo, V, Fofo, H., Hauswirth, W. W., & Williams, D. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.3 · Cited by 112
Phenotypic variability in patients with retinal dystrophies due to mutations in CRB1
Henderson, R. H., Mackay, D. S., Li, Z., Moradi, P., Sergouniotis, P., Russell-Eggitt, I., Thompson, D. A., Robson, A. G., Holder, G. E., Webster, A. R., et al. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.186882 · Cited by 112
Retinoids for treatment of retinal diseases
Palczewski, K. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.03.001 · Cited by 111
Chahal, P. S., Schulze, E., Tran, R., Montes, J., & Kamen, A. A. (2014) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.10.038 · Cited by 111
“…2007; Wagner et al., 002), hemophilia B (Manno et al., 2006, 2003), rheumatoid arthriis (Mease et al., 2010), Leber’s congenital amaurosis (Hauswirth t al., 2008; Maguire et al., 2008; Simonelli et al., 2010) and treatent of lipoprotein lipase deficiency (Mingozzi et al., 2009; Stroes t al., 2008).”
BackgroundBaruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
“Recent clinical successes in various inherited orphan diseases such as Leber’s congenital amaurosis (Bainbridge et al 2008; Cideciyan et al 2008; Maguire et al 2008), X-linked adrenoleukodystrophy (Cartier et al 2009), metachromatic leukodystrophy (Biffi et al 2013) and haemophilia B (Nathwani et…”
BackgroundOptogenetic approaches to vision restoration
Simunovic, M. P., Shen, W., Lin, J. Y., Protti, D. A., Lisowski, L., & Gillies, M. C. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2018.09.003 · Cited by 109
Cone photoreceptor dysfunction in retinitis pigmentosa revealed by optoretinography
Lassoued, A., Zhang, F., Kurokawa, K., Liu, Y., Bernucci, M. T., Crowell, J. A., & Miller, D. T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107444118 · Cited by 123
Genetic etiology and clinical challenges of phenylketonuria
Elhawary, N. A., AlJahdali, I. A., Abumansour, I. S., Elhawary, E. N., Gaboon, N. E. A., Dandini, M., Madkhali, A., Alosaimi, W., Alzahrani, A., Aljohani, F., et al. (2022) · Human Genomics · doi:10.1186/s40246-022-00398-9 · Cited by 111
“has successfully treated several recessive and inherited dominant disorders [173].”
Background
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.